Oppenheimer maintains Olema stock rating, sees Pfizer deal as strategic
Oppenheimer has reaffirmed its stock rating for Olema, viewing the recent Pfizer deal as a strategic move that could benefit the company.
WPN Brief
Oppenheimer has reaffirmed its stock rating for Olema, viewing the recent Pfizer deal as a strategic move that could benefit the company.
Ask WPN AI